Roche Diabetes Care's ACCU-CHEK® Blood Glucose Meters Rank Highest in Overall Satisfaction in Inaugural J.D. Power and

Roche Diabetes Care's ACCU-CHEK® Blood Glucose Meters Rank Highest in Overall
        Satisfaction in Inaugural J.D. Power and Associates Study(SM)

ACCU-CHEK Meters Also Receive Highest Marks in Performance, Ease of Use, Cost
of Test Strips and Training

PR Newswire

INDIANAPOLIS, Feb. 5, 2013

INDIANAPOLIS, Feb. 5, 2013 /PRNewswire/ --Adults living with diabetes in the
United States reported highest satisfaction using Roche Diabetes Care's
ACCU-CHEK products compared with other blood glucose meter manufacturers,
according to the inaugural J.D. Power and Associates 2012 Blood Glucose Meter
Satisfaction Study^SM. Diabetes affects a large portion of the U.S. population
– 25.8 million children and adults or approximately 1 in 12 people.^1 The
study gathered responses from 2,681 current meter users with type 1 and 2
diabetes in the U.S. to determine customer satisfaction across six factors:
performance; ease of use; design; features; cost of test strips; and training.

In addition to achieving the highest in overall satisfaction, ACCU-CHEK blood
glucose meters by Roche, which include the ACCU-CHEK Nano SmartView system,
ACCU-CHEK Aviva Plus and ACCU-CHEK Compact Plus, scored the highest in
performance, ease of use, cost of test strips and training. According to a
J.D. Power and Associates press release announcing the study results,
ACCU-CHEK meters by Roche "perform particularly well in the performance
factor, reflecting a high level of confidence among users that they are
obtaining accurate readings."

"A blood glucose meter is one of the most important tools for people with
diabetes as it empowers them to independently manage their diabetes on a daily
basis," said Debbie Hinnen, a diabetes educator and director of education
services at Mid-America Diabetes Associates. "Therefore, a meter that is
accurate and easy to use is key as it helps to ensure patients make informed
decisions about their meal plan, exercise, insulin use and other lifestyle
challenges."

The survey comes on the heels of two new product launches from Roche in the
past 12 months – ACCU-CHEK Aviva Plus and ACCU-CHEK Nano SmartView systems –
both of which deliver advanced accuracy as tested against a 23% tighter
specification.^2

"Roche is honored by these results because they reflect our unwavering
commitment to providing our customers with the best possible products and
services that fit right into people's lives," said Marc Gibeley, Head of Roche
Diabetes Care North America. "As J.D. Power and Associates is the gold
standard of measuring customer satisfaction, we're humbled by the outstanding
results achieved by ACCU-CHEK meters in its independent analysis."

The 2012 Blood Glucose Meter Satisfaction Study was fielded via an online
survey in October 2012.

About Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood glucose
monitoring systems and a global leader for diabetes management systems and
services. For more than 30 years, Roche has been committed to helping people
with diabetes live lives that are as normal and active as possible and has
been helping healthcare professionals manage their patients' condition in an
optimal way. Today, the ACCU-CHEK portfolio offers people with diabetes and
healthcare professionals innovative products, services and comprehensive
solutions for convenient, efficient and effective diabetes management—from
blood glucose monitoring through information management to insulin delivery.
The ACCU-CHEK brand encompasses blood glucose meters, infusion pumps, lancing
and data management systems. For more information, please visit accu-chek.com.

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused
healthcare with combined strengths in pharmaceuticals and diagnostics. Roche
is the world's largest biotech company, with truly differentiated medicines in
oncology, infectious diseases, inflammation, metabolism and neuroscience.
Roche is also the world leader in in vitro diagnostics and tissue-based cancer
diagnostics, and a frontrunner in diabetes management. Roche's personalized
healthcare strategy aims at providing medicines and diagnostic tools that
enable tangible improvements in the health, quality of life and survival of
patients. In 2012 Roche had over 82,000 employees worldwide and invested over
8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss
francs. Genentech, in the United States, is a wholly owned member of the Roche
Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For
more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

For further information, please contact:

Todd Siesky
Director, Corporate Communications
Roche Diagnostics North America
Indianapolis, IN
(317) 521-3966 O
(317) 361-7637 C
todd.siesky@roche.com

References:

1.Center for Diabetes and Prevention. National Diabetes Fact Sheet.
    Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed
    January 17, 2013.
2.Specifications based on current Internal Organization for Standardization
    (ISO) 15197: 2003.



SOURCE Roche

Website: http://www.roche.com
 
Press spacebar to pause and continue. Press esc to stop.